Additionally, he was receiving a thrombopoietin receptor agonist (eltrombopag), which has been associated with an increased thrombotic risk in patients with immune thrombocytopenia (ITP) [5]. This evidence concerns the gene MPL and autoimmune thrombocytopenic purpura.